

Date: 07.03.1993

Attachment 1.
(FACE SHEET)

ETHICAL REVIEW COMMITTEE, ICDDR,B.

Drs P.K. Bardhan & D. Mahalanabis

Principal Investigator _____ Trainee Investigator (if any) _____

Application No, 93-010 _____ Supporting Agency (if Non-ICDDR,B) _____

Title of Study Evaluation of anti-diarrhoeal Project status:
Effects of Bismuth sub-salicylate in children () New Study
acute non-cholera watery diarrhoea. () Continuation with change
 () No change (do not fill out rest of form)

Circle the appropriate answer to each of the following (If Not Applicable write NA).

1. Source of Population:
 - (a) Ill subjects Yes No
 - (b) Non-ill subjects Yes No
 - (c) Minors or persons under guardianship Yes No
2. Does the study involve:
 - (a) Physical risks to the subjects Yes No
 - (b) Social Risks Yes No
 - (c) Psychological risks to subjects Yes No
 - (d) Discomfort to subjects Yes No
 - (e) Invasion of privacy Yes No
 - (f) Disclosure of information damaging to subject or others Yes No
3. Does the study involve:
 - (a) Use of records, (hospital, medical, death, birth or other) Yes No
 - (b) Use of fetal tissue or abortus Yes No
 - (c) Use of organs or body fluids Yes No
4. Are subjects clearly informed about:
 - (a) Nature and purposes of study Yes No
 - (b) Procedures to be followed including alternatives used Yes No
 - (c) Physical risks Yes No
 - (d) Sensitive questions Yes No
 - (e) Benefits to be derived Yes No
 - (f) Right to refuse to participate or to withdraw from study Yes No
 - (g) Confidential handling of data Yes No
 - (h) Compensation &/or treatment where there are risks or privacy is involved in any particular procedure Yes No
5. Will signed consent form be required:
 - (a) From subjects Yes No
 - (b) From parent or guardian (if subjects are minors) Yes No
6. Will precautions be taken to protect anonymity of subjects Yes No
7. Check documents being submitted herewith to Committee:
 - _____ Umbrella proposal - Initially submit an overview (all other requirements will be submitted with individual studies).
 - ☒ Protocol (Required)
 - ☒ Abstract Summary (Required)
 - ☒ Statement given or read to subjects on nature of study, risks, types of questions to be asked, and right to refuse to participate or withdraw (Required)
 - ☒ Informed consent form for subjects
 - ☒ Informed consent form for parent or guardian
 - _____ Procedure for maintaining confidentiality
 - _____ Questionnaire or interview schedule *

* If the final instrument is not completed prior to review, the following information should be included in the abstract summary:

1. A description of the areas to be covered in the questionnaire or interview which could be considered either sensitive or which would constitute an invasion of privacy.
2. Examples of the type of specific questions to be asked in the sensitive areas.
3. An indication as to when the questionnaire will be presented to the Cttee. for review.

We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.

Prady Bardhan

Principal Investigator

Trainee

SECTION I - RESEARCH PROTOCOL

Title : EVALUATION OF ANTI-DIARRHOEAL EFFECTS OF
BISMUTH SUB-SALICYLATE IN CHILDREN WITH
ACUTE MCN-CHOLERA WATERY DIARRHOEA

Principal Investigator : Dr. P. K. Bardhan
Dr. D. Mahalanabis

Co-Investigators : Dr. S. Samiul Huq
Dr. J. Albert

Consultant : Prof. R. B. Sack
Prof. K. Gyr

Starting Date : As soon as possible

Completion Date : 2 years after starting

Total Direct Cost : US\$ 85,960

Dr. Mahalanabis

Associate Director
Clinical Sciences Division.

Date : March 4, 1993

Summary : Although no specific medications are recommended in acute watery (non-cholera) diarrhoea, a number of non-specific anti-diarrhoeals are currently available, most of which are of limited effectiveness or have undesirable side-effects. There is a substantial amount of evidence that bismuth sub-salicylate is an effective anti-diarrhoeal agent in travellers' diarrhoea and acute watery diarrhoea. This study proposes to assess the antidiarrhoeal effect of bismuth sub-salicylate in children with acute non-cholera watery diarrhoea. A total of 270 children, aged 6 months to 3 years, suffering from acute watery diarrhoea will be studied. The patients will be divided into three groups and a randomised placebo-controlled double-blind clinical trial will be done where each child will receive bismuth sub-salicylate, colloidal bismuth sub-citrate or placebo, and their subsequent clinical course will be monitored and compared. The patients will also be followed up after discharge at home to evaluate any potential preventive effect of the bismuth compounds against recurrence of diarrhoea. It is expected that this study will provide valuable information regarding the anti-diarrhoeal properties of bismuth sub-salicylate.

SECTION II - RESEARCH PLAN

OBJECTIVES

1. GENERAL :

To evaluate the anti-diarrhoeal effect of Bismuth Sub-salicylate (BSS) in acute non-cholera watery in children.

2. SPECIFIC :

Primary :

- a) To examine if BSS reduces stool output and duration of diarrhoea in children suffering from acute non-cholera watery diarrhoeas.
- b) To observe if BSS causes clearance of diarrhoeagenic pathogens in children with acute non-cholera watery.
- c) To evaluate if anti-diarrhoeal effects of BSS (if any) are due to the Bismuth moiety of BSS.

Secondary :

To see if treatment with BSS and Colloidal Bismuth Sub-citrate (CBS) reduces the number of diarrhoeal episodes in the post-treatment follow-up period.

BACKGROUND

Acute diarrhoeal illness are a major cause of morbidity and mortality through out the world. Estimates of the number of deaths worldwide from diarrhoea range from 5 to 10 millions¹. Acute diarrhoea has its greatest impact on the paediatric population, especially in the developing countries. A 1980 WHO study estimated that 0.7 to 1 billion episodes of diarrhoea occur annually in children younger than 5 years of age, with a mortality of 4.6 million per year¹.

Effective rehydration is the treatment of choice in acute childhood diarrhoea irrespective of aetiology, and its use has resulted in dramatic decreases in the morbidity and mortality in developing countries. The WHO has taken the position that 90% of children with watery diarrhoea can be treated safely with oral rehydration therapy. However, oral rehydration therapy does not reduce the amount of stool or duration of diarrhoea². Although a number of non-specific anti-diarrhoeal agents are available, they have limited effectiveness or undesirable side effects. In many instances specific antimicrobial therapy is initially unavailable and the acuteness of the disease demands immediate therapy before the results of diagnostic studies become available. Antibiotics are the agents

most commonly used under these circumstances, often in empiric fashion because they are available "over the counter" in many countries. Their indiscriminate use may result in undesirable side effects and their chronic use results in the development of bacterial resistance. However, if a chemical compound that could lessen the diarrhoeal illness or threat of illness without selecting for the occurrence of resistance were available, this would have important implication for public health. Therefore an important need for safe and effective adjunctive therapy exists.

Bismuth compounds are old drugs that have enjoyed great popularity for at least three centuries. BSS was first used in 1901 in the treatment of "cholera infantum" a common diarrhoeal disease in children. Its subsequent commercial success has been such that it is now estimated by the manufacturer to be a fixture in the medicine cabinet in 60% of American households. Despite this venerable history systematic investigation of the mechanism of action and clinical efficacy of bismuth compounds has only begun in recent years. There is a substantial amount of clinical evidence that bismuth subsalicylate (BSS) is effective in the treatment of diarrhoeal disorders, including studies that have demonstrated a beneficial effect both in the prevention and therapy in traveller's diarrhoea³. Dupont et al.⁴ demonstrated that BSS reduces the frequency of unformed stools, improves stool consistency, and decreases the accompanying symptoms of nausea and abdominal cramps. Steinhoff et al.⁵ inoculated 59 volunteers with the Norwalk agent, an illness characterised by vomiting and diarrhoea; subsequently diarrhoea developed in 34 subjects, who were randomly assigned to a course of BSS or placebo in double-blind fashion. There was a significant reduction in the severity and duration of abdominal cramps and in the median duration of gastro-intestinal symptoms in the group treated with BSS.

BSS has shown promising result in acute diarrhoea, although the studies are rather limited. Soriano-Brucher et al.⁶, studying 123 infants and children with acute diarrhoea in Chile, administered BSS (100 mg/kg/day) for 5 days in a placebo-controlled clinical trial. The BSS group had significant improvements over the placebo group in the following parameters : number of stools/day, requirement of I/V fluids, stool weight and consistency and length of hospital stay. D. Figueroa et al.⁷ has shown in a well-designed placebo-controlled trial with two doses of BSS (100 mg/kg/day, 150 mg/kg/day) over 275 male children, aged 3-59 months with mild to moderate dehydrating watery diarrhoea in Peru that diarrhoea remained prolonged (>5 days after admission) significantly in placebo group, which was three times more than BSS group. Children treated with BSS (at either dose) had clinically important and statistically significant reduction in (i) volume of ORS consumed (20%), (ii) volume of diarrhoeal stools (30%), (iii) duration of diarrhoea (25%), and (iv) duration of hospital stay (about 1 day). It was concluded that BSS may be a clinically useful, safe, and inexpensive adjunct to oral rehydration therapy in children with acute watery diarrhoea.

The mechanism(s) of action of BSS is not completely understood. The possible mechanisms include a direct anti-microbial effect and

anti-secretory and anti-toxin effects.

There is considerable evidence to indicate that BSS has direct antimicrobial activity against diarrhoeal pathogens. Several bacterial pathogens including enterotoxigenic *E. coli*, *Salmonellae*, *Campylobacter jejuni* and *Clostridium difficile* are inhibited *in vitro* by BSS or its metabolic product at concentration that can be achieved in the intestinal tract^{8,9,10}. The isolation of bacterial pathogens from stools of patients with infectious diarrhoea is markedly reduced in BSS-treated patients compared to placebo treated controls. The exact anti-microbial mechanism is not known, though it is believed that bismuth binds to the bacteria, disrupting the cell wall and transmembrane transport. Although bismuth compounds inhibit bacterial pathogens, as well as many of the aerobic and anaerobic bacteria when tested *in vitro*¹¹, no change was noted in the overall composition of the normal flora of the gut or in faeces¹² during BSS administration in therapeutic doses.

BSS was found to significantly reduce fluid accumulation in ligated intestinal loops (rabbit and pig) and unligated intestinal segments (rat) from both *E. coli* and cholera toxins as well as arachidonic acid^{13,14}. This anti-secretory effect may be attributable to the salicylate component of BSS, as this was not found by bismuth subcarbonate. It should be noted that salicylates have been found to be effective anti-secretory agents. Thus it is possible that both the Bismuth and salicylate components of BSS, either alone or together, are responsible for the reported anti-diarrhoeal effects of BSS.

Previously, many compounds of Bismuth were used clinically for symptomatic treatment of diarrhoea, though most of these compounds are no more available now for clinical use. The other Bismuth-containing drug currently available for clinical use besides BSS is Colloidal Bismuth sub-citrate (CBS). CBS has been widely used in the treatment of duodenal and gastric ulcer disease, essential non-ulcer dyspepsia, duodenitis, NSAID-induced disease and *Helicobacter pylori* associated gastro-duodenal disease with high clinical efficacy. Currently, the commonest use of CBS, alone or with combination with antibiotics, is in treatment of *H. pylori* associated gastro-duodenal disease, and long-term eradication of *H. pylori* in upto 95% patients have been reported¹⁵. CBS appears to act via several mechanisms including inhibition of peptic activity, acceleration of ulcer healing, and accumulation of epidermal growth factor in the diseased mucosa¹⁶. However, the most prominent mechanism may be its bactericidal effect against *H. pylori*.

The effect of CBS in diarrhoeal disorders has not been investigated. Like other bismuth compounds, the bismuth part of CBS may have similar actions. That CBS has potent bactericidal action is shown by its effect on *H. pylori*. It has also been shown to be capable of reducing fermentation by colonic bacteria¹¹. A recent report has shown the protective effect of CBS against distal colitis produced experimentally in rats¹⁷. The safety record of CBS is excellent¹⁸, and it has been used in children for eradicating *H. pylori* without any untoward effect¹⁹. Thus, the potential anti-diarrhoeal effect of CBS is worth a trial.

An additional benefit of using bismuth compounds for the treatment of diarrhoeal diseases is the potential preventive effect. Hypochlorhydria is known to be a predisposing factor to repeated gastrointestinal infections²⁰. *H. pylori* is a major cause of gastritis, and a striking association has been noted between the presence of *H. pylori* and gastric hypochlorhydria²¹. In fact, *H. pylori* infection has been shown to be a significant risk-factor for persistent diarrhoea²², and may well be a risk factor for acute diarrhoea. Preliminary results show that *H. pylori* is quite common in the paediatric population in Bangladesh. It is known that children recovering from one diarrhoeal episode are more prone to develop another diarrhoeal episode when compared to healthy children, and thus suppression of *H. pylori* in children suffering from diarrhoea may have some beneficial protective effect upon subsequent development of diarrhoeal episodes.

Safety of BSS and CBS : BSS has been found quite safe and well-tolerated, as evident by the fact that despite being around for a long time, it is still an over-the-counter medicine in most of the countries including USA and UK. CBS has also been found to be a very safe drug, and there is no report of any significant side-effect. Bismuth toxicity is rare, and has only been reported after long-term treatment²³. Bismuth levels in plasma observed after treatment of children with BSS or CBS has been found to be well below toxic levels^{6,7,19,24}. Though the salicylate component of BSS is almost completely absorbed²⁵, no signs of salicylate toxicity have been noted in the previous reports, and serum salicylate levels remain well below toxic levels^{6,7}. No association has been found between Reye's syndrome and the use of BSS or other non-acetylsalicylic acid salicylates^{26,27}.

RATIONALE :

Existing treatment for dehydrating acute watery diarrhoeas in children includes replacement of fluid loss, mainly through oral rehydration therapy (ORT), and appropriate feeding to minimise nutritional consequences. However, they reduce neither the severity nor the duration of diarrhoea. Other than in proven cholera patients, antibiotics are generally not recommended in acute watery diarrhoeas. Thus, it is important to evaluate non-antibiotic antidiarrhoeals. BSS is widely used as an anti-diarrhoeal for decades, and has proven its effect in travellers' diarrhoea. Recent reports have also shown BSS as an effective adjunct in acute diarrhoea in children, where it was found to reduce both the severity as well as the duration of diarrhoea. It is a very safe, non-allergenic, over-the-counter drug, with minimal side-effects, and does not change the normal gut flora. If found useful, this may prove to be a valuable adjunctive therapy to the current management of dehydrating diarrhoeas in children. CBS may have some potential anti-diarrhoeal effects, and comparing such effects with those of BSS will also help to find out whether the bismuth or the subsalicylate moiety of BSS is the major contributor to its anti-diarrhoeal effect. Again, the anti-*H. pylori* effects of BSS

and CBS may be important as protecting against this important risk-factor. A negative outcome of this study will also be helpful, as it will discourage unjustified use of BSS.

MATERIALS AND METHODS

The study will be conducted in the Clinical Research Centre of ICDDR,B. Every year about 70,000 patients are treated in this centre, >60% of whom are below the age of 3 years. The study will be conducted for a period of 36 months from the date of starting the study.

1. PATIENT RECRUITMENT:

Children presenting at the CRC, ICDDR,B with a history of watery diarrhoea will be evaluated and if they fulfil the remaining inclusion and exclusion criteria will be admitted to the study.

(A) INCLUSION CRITERIA:

1. Age : 6 months to 3 years
2. Sex : Males only
3. History of acute watery diarrhoea of <72 hours duration and had 4 or more liquid stools over 24 hours prior to admission.
4. Presence of some signs of dehydration.
5. Nutritional status: Wt. for height > 60 of N.C.H.S. median.

(B) EXCLUSION CRITERIA:

1. Systemic infection requiring prompt antibiotic treatment e.g. pneumonia, meningitis, septicaemia.
2. History of bloody diarrhoea (gross blood in stool).
3. Patients suffering from cholera.
4. Any rehydration therapy (intravenous), antibiotics or antidiarrhoeal drugs given during the week before admission.

(C) INFORMED CONSENT:

If the patient is found suitable for inclusion into the study an informed consent will be obtained (English and Bangla consent form attached). The consent form will be administered by one of the investigators and then will be witnessed by another staff member.

2. CASE MANAGEMENT:

Patients will receive routine care which includes -

- a) Replacement of fluid and electrolytes mainly with ORT supported by I.V. treatment for those who need it;

- b) Unrestricted breast feeding of those still breastfed during rehydration and maintenance therapy;
- c) Formula milk for non-breastfed children starting after initial rehydration period;
- d) Feeding : According to the standard feeding regimen followed in the ICDDR,B hospital for children with diarrhoea, consisting of semisolid and solid food appropriate for age during maintenance fluid therapy.
- e) Medicine : A double-dummy technique will be used in providing BSS/CBS/placebo to the patients in a randomised fashion. Oral BSS will be administered to 90 patients at a dose of 100 mg/kg/day in 5 divided doses daily, and oral CBS to another 90 patients at a dose of 480 mg/1.73 m² of body surface area/day in 5 divided doses daily (6 a.m., 10 a.m., 2 p.m., 6 p.m. and 10 p.m.). In the control group placebos will be given identical in appearance to BSS and CBS to 90 patients in the same dosage schedule. The treatment will continue for 5 days. The individual doses will be worked out on admission (after rehydration) and will be followed for rest of the study.

CRITERIA FOR INTRAVENOUS FLUID:

- 1. Severe dehydration
- 2. In patients whose hydration status cannot be maintained adequately by ORS or patients with intractable vomiting.
- 3. Patients with gross electrolyte imbalance requiring correction by appropriate intravenous fluid.

TREATMENT FAILURE :

Patients still having diarrhoea after full course of treatment (5 days) will be considered as treatment failures. Patients on whom dehydration reappears requiring i.v. hydration or those who develop complications during the course of treatment will constitute as patients with deviated clinical course. Such patients (treatment failures and patients with deviated clinical course) will however receive appropriate management according to the standard ICDDR,B clinical practice.

Summary of Procedures

BASELINE EXAMINATION:

A standard history and a thorough physical examination will be carried out after admitting the patient into the study by one of the investigators. Patient will be weighed and the following investigations will be done.

- a) Blood for T.C., D.C., Hct., serum glucose (random).
- b) Blood for electrolytes (Na^+ , K^+ , Cl^- , TCO_2), serum Sp. Gr., protein (2ml of blood will be required for the tests mentioned).
- c) Fresh stool for microscopy.
- d) Fresh stool for culture for Shigella, Salmonella, Vibrios, E. coli (ETEC, EPEC, EAEC), Aeromonas, Plesiomonas and Campylobacters.
- e) Stool for rotavirus (ELISA)
- f) Intake and output measurements will be instituted using urine bags and cholera cots.
- g) C^{13} -Urea breath test for detection of *H. pylori*.
- h) Faecal α -1-antitrypsin for assessing intestinal protein loss.

DURING THE COURSE OF ILLNESS :

- i) Patients will be evaluated every 8 hours and intake/output measurements will be summarised from tally sheets.
- ii) Patients will be weighed and physical examination findings will be recorded and time of cessation of diarrhoea noted.
- iii) A second blood sample will be taken for serum levels of Bismuth and salicylate on day-6 from every 6th patient, 2-3 hrs after the last dose of medicine.
- iv) Repeat stool examination (Culture + ELISA for RV) on day-6.
- v) Repeat faecal α -1-AT on day-6.

Patients may be discharged earlier if they have recovered from the diarrhoea, but will continue to take medicines at home upto Day-5, and will be brought back to the hospital on Day-6 for the repeat lab. tests.

AFTER DISCHARGE (During follow-up) :

The patients will be followed up every 2 weeks for 3 months after discharge, the first follow-up being on the 15th day after admission. The Urea breath test will be repeated at 3 months to determine the status of *H. pylori*. On each visit, anthropometric measurements will be taken, and a general information of the health of the child during the preceding 2 weeks will be sought. Any recurrence of diarrhoea will be noted and the course will be followed up, if necessary at the hospital.

3. SAMPLE SIZE CALCULATION:

A. If we assume that there will be a 25% reduction of total stool output (ml/kg) in the BSS groups compared to control group, then taking power as 80% and significance level as 0.05 (Stool output 208 ml/kg; S.D. pooled = 113.5).

$$n = \frac{2 \times (113.5)^2}{(52.03)^2} \times 7.9 = 75$$

Assuming a 10% dropout, the total sample size should be 83 in each group.

B. Assuming a 20% reduction in ORS intake in the groups receiving BSS, with 80% power and significance at 0.05% (ORS intake 371 ml/kg, S.D. pooled 161.3), the sample size becomes -

$$n = \frac{2 \times (161.3)^2}{(74.2)^2} \times 7.9 = 75$$

With a 10% dropout, the sample size is 83 per group.

C. We assume that there will be a 20% reduction of duration of diarrhoea in the BSS groups compared to control group. Taking power as 80% and significance level as 0.05 (Mean duration = 92 hours; S.D. = 39).

$$n = \frac{2 \times (39)^2}{(18.4)^2} \times 7.9$$

or 72 in each group.

Assuming a 10% dropout, the total sample size should be 80 in each group.

Thus the sample size is taken as 90 (rounded up) in each of the 3 groups with i.e. a total of 270 patients.

4. RANDOMISATION:

The patients in the study groups will receive rehydration and maintenance fluid along with BSS or CBS, while those in the control will receive rehydration and maintenance fluid with placebos. A double-placebo technique will be used i.e., BSS or its identical placebo and CBS or its identical placebo. Thus the three groups of patients will receive either BSS and CBS-placebo, CBS and BSS-placebo, or BSS-placebo and CBS-placebo. The medicines and their respective placebos will be identical in appearance, packaged in identical containers, and will be dispensed in the same amount. The containers will be arranged in a sequence of drugs and placebos that corresponds to the randomisation code then numbered sequentially. Containers of medicine with serial number will contain drugs or placebo syrup according to master randomisation chart.

Patient group	Receives	Net result
I (90 patients)	BSS + (CBS placebo)	BSS
II (90 patients)	(BSS placebo) + CBS	CBS
III (90 patients)	(BSS placebo) + (CBS placebo)	Placebo

5. OUTCOME VARIABLES:

- * Stool output
- * Fluid Intake - ORS & Plain water
- * Duration of diarrhoea after adm.
- * No. of patients with treatment failure/deviated clinical course.
- * No. of patients with persisting infection after Day 5.
- * Faecal α -1-antitrypsin excretion.
- * Time of first post-discharge diarrhoea, number and duration of diarrhoeal attacks during the 3 months follow-up period

6. DATA ANALYSIS:

The study groups will be compared for all the variables prior to intervention. Major outcome variables will be compared after evaluating their descriptive statistics for distribution etc. The quantitative outcome measures will be compared using ANOVA or Students 't' test on primary data or after appropriate transformation when indicated and also by an equivalent non parametric test e.g. Kruskal-Wallis test or Mann Whitney U test. Dichotomous outcome measures will be compared by X^2 test or Fisher's exact test as appropriate. Time for the first post-discharge diarrhoeal attack will be noted and compared between the three groups with logrank test. Data from the patients declared as treatment failures or with deviated clinical course will be analysed separately.

7. IMPORTANT DEFINITIONS:

1. Duration of diarrhoea after admission: The time in hours from initiation of study treatment until passage of the last liquid or semi-liquid stool prior to two formed stools or prior to 12 hours during which no stool is passed.
2. Stool output: The weight of stool in g/kg of admission body weight expressed per time period (from admission to 24 hours or for entire duration of diarrhoea).
3. ORS and plain water intake: The volume of ORS or plain water taken in ml/kg of admission body weight expressed per time.

8. COLLABORATIVE ARRANGEMENTS :

An inter-institutional collaboration will be arranged with Prof. K. Gyr, University of Basel, Switzerland.

¹³C-Urea Breath Test

This test is based upon the principle that in the presence of the enzyme urease in stomach, orally administered urea will be hydrolysed into CO₂ and ammonia. The CO₂ will be absorbed and excreted in the breath, and if the CO₂ is labelled, then will also be detected in the breath. The urea breath test has proven to be very robust, attaining sensitivity and specificity greater than 90%. This non-radioactive, non-invasive test has been successfully utilised as a diagnostic tool in *H. pylori* infection, including in children.

After obtaining a baseline breath sample at a fasting state (2 hours fast), a test dose alongwith a liquid meal (to delay gastric emptying), and then breath samples will be collected every 10 minutes for 1 hour through a two-way non-rebreathing paediatric mask into vacutainer tubes in duplicate. ¹³CO₂ will be measured in these samples. Increase in the ¹³CO₂/¹²CO₂ ratio in the breath samples after the testdose will indicate a positive test.

REFERENCES

1. Snyder JD, Merson MH. Bull WHO, 1982; 60:605-613
2. WHO. Drug Information Bull; April-June 1985; PDT/DI/85.2
3. Marshall BJ. Am J Gastroenterol; 1991; 86(1):16-25
4. Dupont HL et al. Gastroenterology; 1977; 73:715-718
5. Steinoff MC et al. Gastroenterology; 1980; 78:1495-1499
6. Soriano-Brucher H et al. Pediatrics; 1991; 87(1):18-27
7. Figueroa D et al. (Abs). Proc 1991 ICAAC; 1991; p 224
8. Graham DY et al. Gastroenterology, 1983; 85:1017-1022
9. Manhart MD. Rev Infect Dis, 1990; 12(suppl 1):S11-S15
10. Sox T, Olson CA. Antimicrob Agents Chemother, 1989; 33:2075-82
11. Leon-Barua R et al. Rev Infect Dis, 1990; 12(suppl 1):S24-29
12. Gorbach SL et al. Rev Infect Dis, 1990; 12(suppl 1):S21-23
13. Ericsson CD et al. J Infect Dis, 1977; 136:693-696
14. Gyles CL et al. Can J Compar Med, 1978; 42:260-268
15. Lambert JR. Scand J Gastroenterol, 1991; 26(suppl 185):13-21
16. Lee SP. Scand J Gastroenterol, 1991; 26(suppl 185):1-6
17. Dinari G et al. (Abs). J Pediatr Gastro Nutr, 1992; 15(3):351
18. Benet LZ. Scand J Gastroenterol, 1991; 26(suppl 185):29-35
19. De Giacomo C et al. J Pediatr Gastro Nutr, 1990; 11(3):310-16
20. Sack RB et al. Lancet 1982; ii:527-528
21. Norris A et al. Am J Gastroenterol, 1987; 82:192-199
22. Sullivan PB et al. Arch Dis Child, 1990; 65:189-191
23. Buge A et al. Nouv Presse Med, 1974; 3:2315-2320
24. Hillemand P et al. Semin Hop Paris, 1977; 53:1663-1669
25. Pickering LK et al. J Pediatr, 1981; 99:654-656
26. Institute of Medicine. Report No. 5, 1985; Washington, DC; National Academy of Sciences
27. US Food and Drug Administration. Federal Register, 1988; 53:21633-21637.rm 65

	<u>1st Year</u>	<u>2nd Year</u>	<u>TOTAL</u>
--	-----------------	-----------------	--------------

PERSONNEL

Dr. P. Bardhan	10%	1,215	1,335	
Dr. Samiul Huq	10%	905	995	
Medical Officer (Trainee)	100%	2,210	2,210	
Health Assistant	100%	2,900	3,190	
Trainee Health Asstt	100%	1,525	1,525	
Field Worker	100%	1,525	1,525	
Field Asstt.	100%	950	950	
Total :		11,230	11,730	<u>22,960</u>

LAB TESTS

Blood CBC, HCT		500	300	
Electrolytes		1,900	1,900	
Creat., Sp. Gravity				
Bismuth		200	200	
Salicylate		200	200	
Stool M/E		300	175	
C/S & ELISA for Rota		7,950	3,975	
Faecal α-1-AT		3,950	1,950	
Breath Analysis		2,000	1,000	
Total :		16,950	8,750	<u>25,700</u>

PATIENT HOSPITALISATION

	15,500	7,750	<u>23,250</u>
--	--------	-------	---------------

SUPPLIES AND MATERIALS

Drugs	2,000	-	
Urine collection bags	300	200	
Non-Stock items	300	200	
Stationaries	250	250	
Syringes, Containers, Vials, etc.	350	250	
C ¹³ -Urea	2,000	-	
Total :	5,250	900	<u>6,150</u>

<u>MAIL, FAX, TELEX, etc.</u>	200	300	<u>500</u>
-------------------------------	-----	-----	------------

	<u>1st Year</u>	<u>2nd Year</u>	<u>TOTAL</u>
<u>PRINTING AND PUBLICATION</u>	250	500	<u>750</u>
<u>ICDDR,B TRANSPORT</u>	300	300	<u>600</u>
<u>INTERNATIONAL TRANSPORT</u>	200	200	<u>400</u>
<u>LOCAL TRANSPORT</u>	1,000	500	<u>1,500</u>
<u>DATA ENTRY AND ANALYSIS</u>	500	500	<u>1,000</u>
<u>INTERNATIONAL TRAVEL</u>	-	-	<u>3,000</u>
<u>CAPITAL EXPENDITURE</u>			
File Cabinet (1)	150		
Total :	150	-	<u>150</u>
 <u>GRAND TOTAL</u>	 <u>51,530</u>	 <u>34,430</u>	 <u>85,960</u>

ICDDR - B Protocol Reviewer: Singapore 23 Nov. 1992

Evaluation of Bismuth Sub-Salicylate's anti-diarrhoeal effects in
paediatric patients (acute and persistent diarrhoeas)

Summary: follow-up aspect needs more attention; good rationale
2-level trial proposed (please see last page 4)

Minor comments.

- p1 last line in the developing world
- p2 line 4 in dramatic increases
- p2 improved ORS does reduce stool volume + diarrhoea duration
- p2 line 9 In persistent diarrhoea
- p2 line 11 Although a number ... is available
- p2 line 20 lessen the diarrhoeal illness or threat of illness
- p2 line -2 Its subsequent commercial success ...
- p3 line 7 in Traveller's diarrhoea
- p4 line 1 What has Figueroa shown? (has reported a well-designed)
- p4 line 4 Diarrhoea remained prolonged () three times more
frequently in placebo than BSS groups.
- p5 line 8 salicylates have been found ...
- p5 line -9 Currently, the commonest use ... is in treatment of ...
- p5 line -6 acceleration
- p6 last line no signs of ... have been noted
- p7 line 2 No association has been noted (delete 'been found')
- p7 line 12 consists mostly of dietary manipulation.
- p8 (B) Persistent diarrhoea
- p9 (C) Exclusion criteria
- p9 (h) Why exclude such patients — stratify, if you must.
- p9 Case-management
 - c) is formula milk half strength for 1st 24 hours?
 - d) standardized regime of feeding?
- p10 Dose : since dose depends on kg/ov m^2 , will dose be adjusted daily
(esp persistent diarrhoea) or worked out on day 1 and same dose applied
daily thereafter.

p10 Design

Timing of 5 ~~daily~~ doses per day (.24 does not divide by 5!)?

Why 83 - round up to 90 per treatment group

Yes: see p13
(should be stated earlier!!)

Will double-dummy technique be used? or will children be randomised to a) trial (BSS or CBS) b) treatment within trial

Why 5 days for acute; 7 days for persistent

PLEASE IGNORE SINCE DOUBLE DUMMY PLANNED

360 ELIGIBLE PATIENTS

NE randomisation also needs to be stratified for acute/persistent

a) RANDOMISE

180 eligible patients in BSS trial

180 eligible patients in CBS trial

b) RANDOMISE

b) RANDOMISE

(i) 90 to BSS (ii) 90 to BSS + placebo

(iii) 90 to CBS (iv) 90 to CBS + placebo

double-blind

double-blind

single-blind

single-blind

single-blind

(i) versus (ii) double-blind
(iii) versus (iv) double-blind
(i)/(ii) versus (iii)/(iv) ~~single~~ 1 1/2 blind!

I don't know of a terminology for this comparison

(i) versus (iv)
different treatments but investigator does not know which of (i) & (iv) are active!

Definition of treatment failure.

Why include such definitions

8 hours

(see p

How will 'treatment failures' be handled at analysis
Because definitions of the type 'in any 24 hour period'
- measurements will be in blocks of 16 or 18 hours
or that in practice any consecutive 14 or 13
recording periods. Over 5 days, there are 19 or
14 possible blocks!
Should failure type 3 read 7 days for
persistent diarrhoea cases?

p 11. During course of illness

When will patients be weighed?

What physical exam findings will be recorded,
how frequently in course of illness?

p 12 Follow-up

Methodology of follow-up is poorly described
by whom?

NB

What will be asked every 2 weeks and how recorded?
Will follow-up be every 2 weeks after randomization
or after discharge (some children will take longer to
recover: better to schedule from randomization, else
biased timing dependent upon recovery from initial
episode).

p 12 Sample size

Justify mean and sd.

p 13 Stratification

Only how do we learn that randomization shall be
stratified with $3 \times 83 = 249$ (round up to 270)
cases of acute diarrhoea.

and $3 \times 65 = 195$ (round up to 210)

cases of persistent diarrhoea

480

b Data analysis

Logrank test for time to first diarrhoeal episode post discharge
admission, for how to # pylori found/disappeared post discharge;
distribution of # subsequent diarrhoeal episodes (? treated episodes: define!)

p13 Study size.

No sample size calculations for follow-up


What is the impact of H. pylori on new episodes of diarrhoea (attributable risk)? What is the plausible eradication effect of BSS or CBS & hence reduction in attributable risk? ~~How~~ many children need to be followed up?

a) to assess eradication effect

b) to assess reduction in diarrhoeal episodes

NOTE: if the above calculations gave answers of

1500, not 500 randomized, then you could randomize eligible patients to levels of study as follows



i.e. All females + half males (random half) assigned to LEVEL 1
half males (other half) assigned to LEVEL 2 (the protocol)

i.e. Next detailed study within large, simple trial

* * Even use capture-recapture via your 4% sample to
track readmissions of ^{LEVEL 1} randomized children * *

Next extra

Title: Evaluation of anti-diarrhoeal effects of Bismuth sub-salisyclate in Paediatric population.

Summary of Referee's Opinions: Please see the following table to evaluate the various aspects of the proposal by checking the appropriate boxes. Your detailed comments are sought on a separate, attached page.

Rank Score

	High	Medium	Low
Quality of Project		✓	
Adequacy of Project Design		✓	
Suitability of Methodology		✓	
Feasibility within time period		✓	
Appropriateness of budget	-	-	-
Potential value of field of knowledge		✓	

CONCLUSIONS

I support the application:

a) without qualification ☐

b) with qualification

- on technical grounds ☒

- on level of financial support ☐

Detailed comments

The objectives are to replicate the results of the two previous studies on BSS effects in acute diarrhea from Chile and Peru and to extend the observations to persistent diarrhea. The scientifically most interesting part of this project is to evaluate whether Bismuth or salicylate is the major contributor to any effect seen. The study design is adequate to perceive differences larger than 25% between groups.

Several questions need to be addressed as follows:

1. Why is the age group restricted to 2 year olds. In fact there is a great lack of data in 2-12 year olds. Although this age group is less susceptible to diarrhea it is still an important pediatric group from the point of view of anti diarrheal drug use.
2. Males-only designs are under some attack. It would be desirable to include females in future protocols and use a stool collection device in future studies. I do not expect this study to do this.
3. Why are cholera patients excluded they could be analyzed as a separate group and the study numbers increased. To date there are no data on the effect of BSS on cholera. This would be an important opportunity missed. If data were collected, an increase in the study size and budget would be necessary.
4. There will be a need to decide how to analyze effects by etiology. If there is a serious wish to assess effect by etiology then the study size must be increased substantially. Otherwise comprehensive bacteriology and virology will not be needed except to describe the populations in each group.
5. For persistent diarrhea a 7 day course is probably not adequate and 10 days to 2 weeks should be considered. Follow-up for relapse would be desirable but may not be feasible in this study.
6. Some measurement of recovery of the intestine other than the end of diarrhea would be very desirable. This could be alpha-1-antitrypsin measurements of protein loss or stool lactoferrin or some test for absorption of fat, protein or carbohydrate. This would be of special importance in persistent diarrhea.
7. I assume rice ORS will be used in this study. To date there have been no studies on BSS except with glucose ORS. Since rice-ORS decreases severity and length of illness, it may be difficult to show an effect of BSS. Glucose-ORT should be used to avoid confounding variables.

This protocol is really testing a series of hypotheses which need better articulation. I would understand then implicitly as follows:

Hypotheses

- a) Does bismuth or bismuth and salicylate speed recovery from acute or persistent diarrhoea patients treated with nice-based ORT. To test this hypothesis one would need a glucose-ORS/RSS vs rice-ORS/BSS composition. This has even been done - no data available. Unless addressed specifically, nice-ORT will be a confounding issue.
- b) Is bismuth the active agent or does salicylate contribute to the beneficial effects of BSS on diarrhoea? This hypothesis really should be tested in patients treated with glucose-ORS, best in order to relate findings to previous studies.
- c) Does either BSS or CBS alter the course of persistent diarrhoea?
- d) Does either bismuth or salicylate accumulate to excessive levels in patients treated with BSS or CBS?

An important neglected hypothesis is whether signs of intestinal disorder that could impact on nutrition are altered by BSS or CBS. Clearly the protein loss/intolerance/malabsorption engendered is of great consequence to the health of the child. In a hospitalized setting, such as ICDDR,B, some parameters should be accessible to comment on this.

WBG:sc:mh/REVIEW

RESPONSE TO REVIEWERS' COMMENTS

Reviewer 1.

1. Appropriate corrections have been made.
2. Patients to be excluded from the study are those who have complications or are otherwise likely to receive antibiotics or other specific medicines.
3. Feeding of the children will be according to the standard regime followed in the ICDDR,B.
4. The dose schedule will be worked out on Day 1 after rehydration and will be adhered to for the duration of the study.
5. Patients with diarrhoea after full 5 days treatment will be considered as treatment failures. Patients who develop dehydration during treatment requiring i.v. fluids or developing complications will constitute as deviated course. Data from patients with treatment failure or deviated course will be analysed separately.
6. Measurements of inputs, outputs, vital signs, etc. are done 8 hourly as a standard practice. The patients are weighed before and after rehydration, and then daily till discharge from the hospital. Physical examinations are done as frequently as necessary, but at least twice daily.
7. Follow-up methodology is now provided in greater detail. The data will be recorded in a pre-designed form. Follow-up will be done every 2 weeks after randomization.
8. Sample sizes are rounded up as suggested.
9. Data analysis will be performed as suggested.
10. Examination of any preventive effect of bismuth compounds on diarrhoea will need a properly designed separate study. There is still not enough evidence to treat anybody with H. pylori and any symptom other than dyspepsia/peptic ulcer disease. Assessment of any potential preventive effect of BSS/CBS on diarrhoea is a secondary objective in the present study.

Reviewer 2.

1. Children suffering from acute diarrhoea are mostly less than 3 years of age. The age group for acute diarrhoea has therefore been extended upto 3 years.
2. Because of inadequacy of the stool collection device now available, males-only design has been retained.
3. The present study aims at examining the effects of BSS on those type of childhood diarrhoeas for which no specific medicines are recommended. Appropriate antibiotics are generally recommended in cholera, and assessing the effect of BSS on cholera may need a seperate study.
4. The microbiological laboratory examinations required in the present study are mostly for descriptive purpose, and the repeat examinations are to examine the clearance of the responsible organism, if any.
5. Faecal alpha-1-antitrypsin will be assayed as suggested.
7. Rice-ORS is currently used in the ICDDR,B as the standard in ORT, and also will be used in the study.